<DOC>
	<DOC>NCT01564706</DOC>
	<brief_summary>This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.</brief_summary>
	<brief_title>A Study of 18F-AV-45 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Able to lie still on the imaging table for periods up to 1 hour Radiation exposure for experimental purposes within the last year Claustrophobic or otherwise unable to tolerate the imaging procedure Medical condition or surgical history that would confound evaluation Current clinically significant cardiovascular disease Received an investigational medication within the last 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Amyloid imaging</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>18F-AV-45</keyword>
	<keyword>florbetapir F 18</keyword>
	<keyword>Diagnostic imaging</keyword>
</DOC>